ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

UTHR United Therapeutics Corporation

229.54
-13.73 (-5.64%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,114,801
Bid Price 227.50
Ask Price 242.00
News -
Day High 243.57

Low
204.44

52 Week Range

High
261.54

Day Low 229.14
Company Name Stock Ticker Symbol Market Type
United Therapeutics Corporation UTHR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-13.73 -5.64% 229.54 20:00:00
Open Price Low Price High Price Close Price Prev Close
243.57 229.14 243.57 229.72 243.27
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
19,977 1,114,801 $ 235.48 $ 262,514,700 - 204.44 - 261.54
Last Trade Time Type Quantity Stock Price Currency
19:58:41 4 $ 229.53 USD

United Therapeutics (UTHR) Options Flow Summary

Overall Flow

Bearish

Net Premium

-7M

Calls / Puts

116.67%

Buys / Sells

66.67%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

United Therapeutics Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
10.81B 47.06M - 2.33B 984.8M 20.93 10.98
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

United Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No UTHR Message Board. Create One! See More Posts on UTHR Message Board See More Message Board Posts

Historical UTHR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week237.06250.89229.14243.21513,907-7.52-3.17%
1 Month228.59250.89223.52238.23532,1570.950.42%
3 Months228.09250.89208.6249227.56409,5501.450.64%
6 Months232.85258.31208.6249228.78358,010-3.31-1.42%
1 Year218.48261.54204.44226.97360,67011.065.06%
3 Years169.77283.09158.38217.04400,70559.7735.21%
5 Years116.81283.0974.31167.64429,444112.7396.51%

United Therapeutics Description

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Your Recent History

Delayed Upgrade Clock